Innova Captab Ltd (INNOVACAP) is currently trading at 1,035.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Innova Captab Limited is an integrated Indian pharmaceutical company operating as a CDMO and as a branded generics player, with manufacturing facilities in Baddi and a greenfield facility in Kathua, Jammu, plus R&D capabilities and an expanding international footprint. Q1 FY27 delivered a strong operational beat: consolidated revenue of INR470.9 crores (up 34% YoY), EBITDA of INR75.1 crores (33% YoY) at a 16% margin, and PAT of INR44.1 crores (up 42% YoY), signaling robust demand across CDMO and branded generics businesses and meaningful operating leverage. The Jammu (Kathua) facility is a transformational asset: it generated ~INR107 crores in Q1 FY27, is annualized at roughly 25–30% utilization, has achieved positive EBITDA, and management projects an optimum revenue potential near INR1,400 crores at 65–70% utilization, highlighting a multi‑year ramp opportunity. Exports contributed 32% of revenue this quarter and the company is investing selectively in complex dosage capabilities, formulation development, and regulatory approvals; R&D is steady albeit modest at roughly 0.7–1% of revenue, with management citing pipeline work including semaglutide development efforts. Management emphasizes disciplined capital allocation and phased capex: routine maintenance capex of INR20–25 crores and growth/debottlenecking capex of INR20–30 crores annually, while larger greenfield decisions will be taken with board approval and announced when firmed up.

Over the past 52 weeks, Innova Captab Ltd has traded between a low of ₹608.25 and a high of ₹1,350.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Innova Captab Ltd has a market capitalization of approximately 6,012.62. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Innova Captab Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.04 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6,012.62 Cr, Innova Captab Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Innova Captab Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Innova Captab Ltd is 39.04. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company revised results after identifying inadvertent accounting errors, mainly involving deferred tax liabilities linked to a historical business combination and a deferred tax asset under Section 80JJAA.

The company said it identified inadvertent accounting errors, mainly involving deferred tax items and the classification of supplier finance balances, and approved revised audited results for FY26 and Q4FY26.

The company said it identified inadvertent accounting errors, mainly linked to deferred tax liabilities from a historical business combination and recognition of a deferred tax asset under Section 80JJAA.

The board meeting was scheduled for August 11, 2026 to approve unaudited standalone and consolidated results for the quarter ended June 30, 2026 and to consider revised audited standalone results for FY ended March 31, 2026.